Patient associations argue “If Xalkori is introduced in the National Health Insurance Committee…”
The Pfizer’s non-small cell lung cancer treatment ‘Xalkori (generic name: crizotinib)’ has gotten closer to application of the National Health Insurance Service. It is expected that the benefit will be provided if the beneficiary case is decided at the National Health Insurance Evaluation Committ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
